--- title: "MAIA Biotechnology cuts at-the-market program to $11,200,000 from $30,000,000" url: "https://aibio.space/news/maia-biotechnology-cuts-market-program-11-200-000-30-000-000/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-03-26" section: "Financings" tickers: "AMEX:MAIA" source: "https://www.sec.gov/Archives/edgar/data/1878313/000164117225000776/form424b5.htm" summary: "The smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far." --- By the aibio.space news desk. Sources - [MAIA Biotechnology, Inc. 424B5 (2025-03-26)](https://www.sec.gov/Archives/edgar/data/1878313/000164117225000776/form424b5.htm) - [MAIA Biotechnology, Inc. 8-K (2025-03-26)](https://www.sec.gov/Archives/edgar/data/1878313/000164117225000788/form8-k.htm) [MAIA](https://aibio.space/companies/maia-biotechnology/) 2025-03-26 # MAIA Biotechnology cuts at-the-market program to $11,200,000 from $30,000,000 Tickers [MAIA](https://aibio.space/companies/maia-biotechnology/) The smaller size reflects an SEC limit tied to MAIA's public float. The company has sold about $11,633,086 of stock under the agreement so far. ## Key facts - **Company**: MAIA Biotechnology, Inc. (AMEX: MAIA) - **News type**: Financings - **Primary source**: [MAIA Biotechnology, Inc. 424B5 (2025-03-26)](https://www.sec.gov/Archives/edgar/data/1878313/000164117225000776/form424b5.htm) *Midtown Manhattan and a downtown tower in haze. CC0, via rawpixel. The picture shows the field, not the companies named.* MAIA Biotechnology, Inc. reduced the maximum size of its at-the-market share sales program with H.C. Wainwright & Co. LLC from $30,000,000 to $11,200,000 on March 26, 2025, according to a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1878313/000164117225000788/form8-k.htm). In an at-the-market program, a company sells new shares into the market at prevailing prices through a broker over time. MAIA's agreement with Wainwright is dated February 14, 2024. The company said it had sold shares with an aggregate sales price of approximately $11,633,086 under the agreement in total, including approximately $6,289,062 in the last 12 months. The cut follows General Instruction I.B.6 of Form S-3. Under it, MAIA will not sell more than one-third of its public float in a public primary offering in any 12-month period while that float is below $75.0 million. The [prospectus supplement](https://www.sec.gov/Archives/edgar/data/1878313/000164117225000776/form424b5.htm) puts MAIA's public float at approximately $52,673,686, based on 25,082,708 non-affiliate shares at $2.10, the February 5, 2025 closing price. After its earlier sales, MAIA said it is eligible to sell up to approximately $11,268,834. MAIA's common stock trades on the NYSE American under the symbol "MAIA." The last reported sale price on March 25, 2025 was $1.57 per share. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story MAIA MAIA Biotechnology, Inc. AMEX ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/maia-biotechnology-cuts-market-program-11-200-000-30-000-000/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MAIA Biotechnology cuts at-the-market program to $11,200,000 from $30,000,000", 2025-03-26, https://aibio.space/news/maia-biotechnology-cuts-market-program-11-200-000-30-000-000/